Cadrenal Therapeutics (CVKD) has retained Tungsten Advisors to lead a formal evaluation of strategic alternatives, including potential partnerships and asset sales, as its pipeline matures following FDA alignment on CAD-1005. This development highlights the Company's proactive approach to maximizing shareholder value amidst significant industry interest.